- cafead   Nov 10, 2023 at 10:22: AM
via Inovio Pharmaceuticals has a line of sight on an accelerated approval. Weeks after getting the green light to use data from a completed single-arm phase 1/2 clinical trial to support a filing, the DNA medicine specialist has set out what the opening up of the regulatory pathway means for its rare disease drug.
article source
article source